Your browser doesn't support javascript.
loading
Improved detection of synthetic lethal interactions in Drosophila cells using variable dose analysis (VDA).
Housden, Benjamin E; Li, Zhongchi; Kelley, Colleen; Wang, Yuanli; Hu, Yanhui; Valvezan, Alexander J; Manning, Brendan D; Perrimon, Norbert.
  • Housden BE; Living Systems Institute, University of Exeter Medical School, University of Exeter, Exeter, United Kingdom EX4 4QD; b.housden@exeter.ac.uk perrimon@genetics.med.harvard.edu.
  • Li Z; Department of Genetics, Harvard Medical School, Boston, MA 02115.
  • Kelley C; Department of Genetics, Harvard Medical School, Boston, MA 02115.
  • Wang Y; Department of Genetics, Harvard Medical School, Boston, MA 02115.
  • Hu Y; Department of Genetics, Harvard Medical School, Boston, MA 02115.
  • Valvezan AJ; Department of Genetics, Harvard Medical School, Boston, MA 02115.
  • Manning BD; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115.
  • Perrimon N; Department of Genetics and Complex Diseases, Harvard T. H. Chan School of Public Health, Boston, MA 02115.
Proc Natl Acad Sci U S A ; 114(50): E10755-E10762, 2017 12 12.
Article en En | MEDLINE | ID: mdl-29183982
ABSTRACT
Synthetic sick or synthetic lethal (SS/L) screens are a powerful way to identify candidate drug targets to specifically kill tumor cells, but this approach generally suffers from low consistency between screens. We found that many SS/L interactions involve essential genes and are therefore detectable within a limited range of knockdown efficiency. Such interactions are often missed by overly efficient RNAi reagents. We therefore developed an assay that measures viability over a range of knockdown efficiency within a cell population. This method, called Variable Dose Analysis (VDA), is highly sensitive to viability phenotypes and reproducibly detects SS/L interactions. We applied the VDA method to search for SS/L interactions with TSC1 and TSC2, the two tumor suppressors underlying tuberous sclerosis complex (TSC), and generated a SS/L network for TSC. Using this network, we identified four Food and Drug Administration-approved drugs that selectively affect viability of TSC-deficient cells, representing promising candidates for repurposing to treat TSC-related tumors.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Genes Supresores de Tumor / Interferencia de ARN / Drosophila / Epistasis Genética / Genes Letales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Ensayos de Selección de Medicamentos Antitumorales / Genes Supresores de Tumor / Interferencia de ARN / Drosophila / Epistasis Genética / Genes Letales Tipo de estudio: Diagnostic_studies / Prognostic_studies Límite: Animals / Humans Idioma: En Año: 2017 Tipo del documento: Article